GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Other Gross PPE

Labiana Health (XMAD:LAB) Other Gross PPE : €4.33 Mil (As of Dec. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Other Gross PPE?

Labiana Health's Other Gross PPE for the quarter that ended in Dec. 2022 was €4.33 Mil.

Labiana Health's quarterly Other Gross PPE increased from Dec. 2021 (€4.05 Mil) to Jun. 2022 (€4.12 Mil) and increased from Jun. 2022 (€4.12 Mil) to Dec. 2022 (€4.33 Mil).

Labiana Health's annual Other Gross PPE increased from Dec. 2020 (€3.74 Mil) to Dec. 2021 (€4.05 Mil) and increased from Dec. 2021 (€4.05 Mil) to Dec. 2022 (€4.33 Mil).


Labiana Health Other Gross PPE Historical Data

The historical data trend for Labiana Health's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Other Gross PPE Chart

Labiana Health Annual Data
Trend Dec20 Dec21 Dec22
Other Gross PPE
3.74 4.05 4.33

Labiana Health Semi-Annual Data
Dec20 Dec21 Jun22 Dec22
Other Gross PPE 3.74 4.05 4.12 4.33

Labiana Health Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Labiana Health (XMAD:LAB) Business Description

Traded in Other Exchanges
N/A
Address
Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.